Abstract 399O
Background
Previous studies stating the combination of oxaliplatin and fluoropyrimidines as the standard of care for the adjuvant therapy of stage III colon cancer (CC) patients (pts) obtained non-convergent results and a reduced benefit for those over the age of 70 years.
Methods
We have assessed the impact of age (categorized as < or ≥ 70 years) on relapse free interval (RFI), defined as time from random to relapse or last disease assessment, in stage III CC pts randomized to receive 3 or 6 months of FOLFOX (FULV plus oxaliplatin) or CAPOX (capecitabine plus oxaliplatin) in the Italian, multicenter, phase III, TOSCA study (clinicaltrials.gov NCT0064660).
Results
3,759 pts were enrolled from 130 sites. Overall, 2,360 of them had stage III disease, including 1,667 aged under 70 and 693 aged 70 or over. The elderly had an ECOG performance status (PS) more often equal to 1 (10.5% vs 3.3%, p <0.001), fewer women (40.8% vs 45.1, p=0.057), more T3/T4 tumors (90.9% vs 84.3%, p<0.001), a greater number of poorly differentiated (G3) tumors (28.3% vs 24.2%, p=0.039) and located on the right (40.9% vs 26.6%, p <0.001). No variation for type and treatment arm (p=0.965) was observed. The median follow-up was 62.5 and 60.6 months for the under 70 and the over 70, respectively. In pts over 70, we found a greater proportion of dose reductions (46.7% vs 41.4%, p=0.018), treatment interruptions (26.1% vs 19.3%, p<0.001) and a higher proportion of recurrences (24.2% vs 20.3%, p=0.033). The multivariable analysis of the RFI, corrected for sex, ECOG PS, tumor site, stage, grade, treatment, treatment duration and dose reduction, does not indicate a statistically significant effect of age (HR 1.19, 95% CI 0.98-1.44, p=0.082), although the point estimate is not negligible. Only a stage III high risk CC had a significant impact on RFI (HR [vs low risk] 2.05, 95% CI 1.71-2.46, p<0.001).
Conclusions
Comparing to younger pts, in elderly stage III CC pts treated with an oxaliplatin-based adjuvant therapy, a different treatment tolerability and a potential reduction of benefit was highlighted. Considerations should be made about the patient's general health status, his comorbidities and the management of the expected side effects.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
GISCAD.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
396O - Health-related quality of life (HRQoL) in patients (pts) treated with pembrolizumab (pembro) vs chemotherapy as first-line treatment in microsatellite instability-high (MSI-H) and/or deficient mismatch repair (dMMR) metastatic colorectal cancer (mCRC): Phase III KEYNOTE-177 study
Presenter: Thierry André
Session: Proffered Paper - GI, colorectal
Resources:
Abstract
Slides
Webcast
397O - Avelumab plus cetuximab in pre-treated RAS wild type metastatic colorectal cancer patients as a rechallenge strategy: The phase II CAVE (cetuximab-avelumab) mCRC study
Presenter: Erika Martinelli
Session: Proffered Paper - GI, colorectal
Resources:
Abstract
Slides
Webcast
398O - Effect of 5 years of imaging and CEA follow-up to detect recurrence of colorectal cancer (CRC) - PRODIGE 13 a FFCD phase III trial
Presenter: Come Lepage
Session: Proffered Paper - GI, colorectal
Resources:
Abstract
Slides
Webcast
Invited Discussant 396O and 397O
Presenter: Chiara Cremolini
Session: Proffered Paper - GI, colorectal
Resources:
Slides
Webcast
Q&A and live discussion
Presenter: Michel Ducreux
Session: Proffered Paper - GI, colorectal
Resources:
Webcast
Invited Discussant 398O and 399O
Presenter: Timothy Price
Session: Proffered Paper - GI, colorectal
Resources:
Slides
Webcast
Q&A and live discussion
Presenter: Michel Ducreux
Session: Proffered Paper - GI, colorectal
Resources:
Webcast